Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).

BMC Cancer · 2020 · PMC7268753 · PMID 32487035

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Recently, the KEYNOTE-062 could not demonstrate superiority of pembrolizumab added to chemotherapy in 1st line CPS > 1 EGA despite a favorable trend [ 22 ].

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.